pharma | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants

DAILY UPDATE: United Health Investigated as Stock Markets Climb

Posted on July 26, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?

REFER A COLLEAGUE: MarcinkoAdvisors@outlook.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

Your Referral Count -0-

CITE: https://www.r2library.com/Resource

UnitedHealth confirmed it’s being investigated. The healthcare giant said in a securities filing that it’s cooperating with the Justice Department in civil and criminal investigations following recent reports from the Wall Street Journal that the DOJ was looking into the company’s Medicare billing practices. WSJ reported that UnitedHealth had added unnecessary diagnoses to Medicare patients’ records that increased payments. It’s the latest setback for a company that ousted its CEO in May after its stock price cratered.

CITE: https://tinyurl.com/2h47urt5

What’s up

Tesla arrested its latest decline and gained 3.52% on the news that it will roll out its new robotaxi program in San Francisco as soon as this weekend.
Palantir rose 2.54% to become the 20th most valuable company in the country by market value.
Deckers Outdoor, the maker of Hoka and Ugg shoes, soared 11.35% on the back of stronger-than-expected earnings thanks to impressive international sales.
Newmont climbed 6.89% after a quarter of surging gold prices helped propel the miner’s earnings to new heights.
Managed care provider Centene added 6.09% despite marked declines in its Medicaid and Medicare membership, as well as soaring costs.
Boston Beer rose 6.54% as shareholders raised a toast to management’s effort to keep tariff costs low.

What’s down

Intel fell 8.53% on the news that it’s cutting costs by laying off 15% of its workforce and scaling back its chip foundry plans.
Puma plummeted 15.67% after the European footwear company warned of the high cost of tariffs.
Charter Communications plunged 18.49% in its worst day of trading ever after reporting that it lost 117,000 broadband subscribers last quarter. It was so bad that other cable stocks like Comcast sank 4.78% and Altice lost 9.46%.
Lyft announced it’s rolling out new autonomous shuttles, but shares still fell 0.56% as shareholders realized it’s just trying to keep up with Uber.

CITE: https://tinyurl.com/tj8smmes

Visualize: How private equity tangled banks in a web of debt, from the Financial Times.

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@outlook.com

Thank You

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

Filed under: Drugs and Pharma, Ethics, Information Technology, Investing, Marcinko Associates, Recommended Books, Sponsors | Tagged: billing medicare, DJIA, DOJ, DOW, Drugs, Justice, Marcinko, medicare, NASDAQ, Optum, PBMs, pharma, S&P 500, textbooks, UHC, VIX, WSJ | Leave a comment »

CRISIS MANAGEMENT: Definition with Big Pharma Example

Posted on June 18, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

***

By Dr. David Edward Marcinko MBA MED CMP™

SPONSOR: wwwCertifiedMedicalPlanner.org

***

Crisis Management is the precautions and identification of threats to an organization and its stakeholders, and the methods used by the organization to deal with these threats.

For example, recall in 1982, that Tylenol™ commanded 35 percent of the over-the-counter analgesic market in America and it represented nearly 17 percent of Johnson & Johnson’s profits. But, when seven people died from consuming the tainted drug, a national panic ensued. Moreover, Americans started to question the safety of all over-the-counter medications.

MARKETING, ADVERTISING & SALES: Public Relations, Change and Crisis Management

Fortunately, J&J commenced the proto-typical good crisis response in the following way:

J&J acted quickly, with complete candidness about what happened and within hours of learning of the deaths, J&J installed toll-free numbers for consumers, sent alerts to healthcare providers nationwide, and stopped advertising the product. J&J recalled 31 million bottles of Tylenol™ capsules and offered replacement products free of charge. J&J did not wait for evidence to see whether the contamination might be more widespread.

J&J’s leadership was in the lead and seemed in full control throughout the crisis. The chairman was admired for his leadership to pull Tylenol™ capsules off the market and his forthrightness in dealing with the media. The Tylenol™ crisis led the news every night on every station for six weeks.

J&J placed consumers first. J&J spent more than $100 million for the recall and re-launch of Tylenol™. The stock had been trading near a 52-week high just before the tragedy, dropped for a time, but recovered to its highs only two months later.

J&J accepted responsibility. The disaster could have been described in many different ways: as an assault on the company, as a problem somewhere in the process of getting Tylenol™ from J&J factories to retail stores, or as the acts of a crazed criminal.

J&J sought to ensure that measures were taken to prevent a recurrence of the problem. J&J introduced tamper-proof packaging that would make it much more difficult for a similar incident to occur in the future.

J&J presented itself prepared to handle the short-term damage in the name of consumer safety. Within a year of the disaster, J&J’s share of the analgesic market, which had fallen to 7 percent from 37 percent following the poisoning, had climbed back to 30 percent.

This wildly successful response in now the stuff of graduate and business school case models for excellence in teaching!

EDUCATION: Books

SPEAKING: Dr. Marcinko will be speaking and lecturing, signing and opining, teaching and preaching, storming and performing at many locations throughout the USA this year! His tour of witty and serious pontifications may be scheduled on a planned or ad-hoc basis; for public or private meetings and gatherings; formally, informally, or over lunch or dinner. All medical societies, financial advisory firms or Broker-Dealers are encouraged to submit a RFP for speaking engagements: MarcinkoAdvisors@outlook.com

COMMENTS APPRECIATED

Like, Subscribe and Refer

***

Filed under: "Ask-an-Advisor", Ask a Doctor, CMP Program, Drugs and Pharma, Ethics, finance, Investing, Touring with Marcinko | Tagged: advertising, Change, CMP, crisis management, engage, investments, J&J, listen, Marcinko, marketing, measure, PBMs, pharma, sales, talk, Tylenol | Leave a comment »

DAILY UPDATE: Kennedy on Vaccines & Google Search as Stock Markets Rise!

Posted on June 13, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?

REFER A COLLEAGUE: MarcinkoAdvisors@outlook.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

Your Referral Count -0-

FRIDAY 13th

CITE: https://www.r2library.com/Resource

Robert F. Kennedy Jr. appointed eight new members to a panel that advises the government on vaccines after firing the entire 17-member group.

Google offered buyouts to US employees in its Search and other divisions as it looks to cut costs.

CITE: https://tinyurl.com/2h47urt5

🟢 What’s up

Oracle popped 13.31% after the cloud computing giant beat Wall Street forecasts on both the top and bottom lines last quarter.
Cardinal Health climbed 4.55% after the healthcare products maker raised its fiscal guidance for the year.
CureVac NV exploded 37.59% on the news that BioNTech will acquire the pharma company in an all-stock deal worth $1.25 billion.
Datadog rose 3.43% thanks to an upgrade from analysts at Wolfe Research, who think the cybersecurity company has an opportunity for rapid growth thanks to AI.

What’s down

Boeing sank 4.79% after an Air India 787 flying from Ahmedabad to London crashed with 242 people aboard. Engine maker GE Aerospace fell 2.25% as well.
GameStop plummeted 22.45% after the video game retailer announced late yesterday that it will sell $1.75 billion in convertible bonds to buy more bitcoin.
Speaking of raising money, nuclear startup Oklo fell 5.22% on the news that it will sell $400 million of common stock in a public offering.
Oxford Industries, parent company of Tommy Bahama and Lily Pulitzer, dropped 14.03% after cutting its fiscal guidance due to tariffs.

CITE: https://tinyurl.com/tj8smmes

Visualize: How private equity tangled banks in a web of debt, from the Financial Times.

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@outlook.com

Thank You

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

Filed under: Drugs and Pharma, Ethics, Information Technology, Investing, Marcinko Associates, Recommended Books, Sponsors | Tagged: CDC, DJIA, DOW, Drugs, Google Search, Kennedy, Marcinko, NASDAQ, pharma, S&P 500, stock markets, stocks up, textbooks, vaccines | Leave a comment »

UNITEDHEALTH GROUP CEO: Quits and Suspends Annual Forecast

Posted on May 13, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

BREAKING NEWS

***

UnitedHealth Group just announced the exit of CEO Andrew Witty and suspended its 2025 forecast due to surging medical costs, sending its shares down more than 10%. Chairman Stephen Hemsley will become CEO, effective immediately.

Medicare Advantage: https://medicalexecutivepost.com/2024/10/11/medicare-advantage-part-c-plans-face-headwinds/

The fourth-largest U.S company big revenue in 2024, Minnetonka-based UnitedHealth has experienced a turbulent year that saw the shock killing of United Healthcare CEO Brian Thompson in New York City, and a cyberattack that affecting an estimated 190 million people and cost the company an estimated $3.1 billion dollars.

UnitedHealth: https://medicalexecutivepost.com/2025/04/17/unitedhealth-stock-dives/

COMMENTS APPRECIATED

Subscribe, Like and Refer

***

Filed under: "Ask-an-Advisor", Accounting, Breaking News, Drugs and Pharma, Ethics, Glossary Terms, Health Economics, Health Insurance, Healthcare Finance, Information Technology, Investing | Tagged: Andrew Witty, Brian Thompson, cyber attacks, Drugs, medicare, Medicare Advantage, Part C, pharma, Stephen Hemsley, UnitedHealth Group | Leave a comment »

TRUMP: Brings Down Prescription Drug Costs

Posted on May 12, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters and ChatGPT

***

***

President Trump to bring down prescription costs

In a Sunday post to Truth Social, President Trump signed an executive order at 9 am today to institute a most-favored-nation policy with pharmaceutical companies that he predicted could lower drug prices by 30% to 80%.

PBMs: https://medicalexecutivepost.com/2022/01/15/podcast-pharma-rebates-to-pbms/

“The United States will pay the same price as the Nation that pays the lowest price anywhere in the World,”

While Americans pay more for pharmaceuticals than any other country, Bloomberg reported that the American market fuels innovation and drives growth in the industry. Drug makers have pushed back on previous efforts to revamp the system in the US, saying it would make revenue evaporate and hinder the development of potentially lifesaving drugs.

WEIGHT LOSS: https://medicalexecutivepost.com/2023/10/24/weight-loss-drugs-for-kids-stocks-for-adults/

COMMENTS APPRECIATED

Like and Refer

***

Filed under: Ask a Doctor, Drugs and Pharma, Health Economics, Health Insurance, LifeStyle | Tagged: Bloomberg, drug costs, drug makers, Drugs, pharma, pharmaceuticals, PMBs, Trump, Truth Social | Leave a comment »

DAILY UPDATE: Merck and the Surging Stock Markets

Posted on April 25, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?

REFER A COLLEAGUE: MarcinkoAdvisors@outlook.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

Your Referral Count -0-

CITE: https://www.r2library.com/Resource

Merck rose 1.40% today after beating earnings expectations. The problem is that the pharma giant expects a $200 million hit to its bottom line due to tariffs. And that doesn’t count the potential additional pharmaceutical levies Trump has indicated he’s planning.

CITE: https://tinyurl.com/2h47urt5

🟢 What’s up

Alphabet warned some remote employees that they must return to the office three days a week or lose their jobs. Shareholders clearly approve: The stock gained 2.53%.
Amazon and Nvidia executives made it clear that contrary to popular belief, demand for AI data centers isn’t slowing down. Amazon rose 3.29%, while Nvidia climbed 3.62%.
Newmont gained 4.80% after the gold miner reported strong earnings thanks to gold’s incredible run.
ServiceNow soared 15.49% after the enterprise tech company posted a beat-and-raise earnings report.
Texas Instruments popped 6.56% thanks to a strong first quarter and healthy fiscal guidance from the domestic semiconductor company.
Chipotle eked out a 1.60% gain despite a mixed quarter that saw same-store sales fall for the first time since 2020.

What’s down

IBM topped analyst expectations on sales and profits, but the tech stock fell 6.58% thanks to a poor performance from its consulting and its mainframe businesses.
Nokia tumbled 8.65% following a big earnings miss last quarter, and warned that tariffs will take a serious toll on its business this quarter.
Fiserv plunged 18.52% after the software provider beat expectations for profits but missed on revenue.
Procter & Gamble outpaced Wall Street’s forecast for earnings but fell short on revenue and cut its fiscal guidance, pushing shares of the consumer goods giant down 3.74%.
Comcast also beat analyst estimates on both the top and bottom lines, but sank 3.71% after reporting it lost 199,000 broadband customers last quarter.

CITE: https://tinyurl.com/tj8smmes

Warren Buffett owns 5% of all Treasury bills—more than the Federal Reserve
A list of every company that’s announced it’s moving manufacturing to the US
Home sales fell 5.9% in March, their biggest drop since 2022
The $TRUMP crypto surged over 50% after President Trump invited the coin’s top 220 holders to a private dinner
Durable goods orders, AKA purchases of big-ticket items like autos and aircraft, popped 9.2% as people rushed to buy ahead of tariffs
Speaking of, US liquor exports surged 10% to a record $2.4 billion

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@outlook.com

Thank You

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

Filed under: Drugs and Pharma, Ethics, Information Technology, Investing, Marcinko Associates, Recommended Books, Sponsors | Tagged: Buffett, credit card, credit report, crypto, DJIA, DOW, Drugs, free-credit-report, FTC, identity theft, identity-theft-protection, Marcinko, Merck, NASDAQ, P&G, pharma, S&P 500, textbooks | Leave a comment »

HOSTILE COMPANY TAKEOVER: Definition, Defense & Pharmaceutical Company Example

Posted on March 24, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

SPONSOR: http://www.MarcinkoAssociates.com

***

SPONSOR: http://www.HealthDictionarySeries.org

A hostile takeover happens when an entity takes control of a company without the knowledge and against the wishes of the company’s management. A hostile takeover is an acquisition strategy requiring that the entity acquire and control more than 50% of the voting shares issued by the company.

In mergers and acquisitions (M&A), a hostile takeover is the acquisition of a target company by an acquiring company that goes directly to the target company’s shareholders, either by making a tender offer or through a proxy vote.

Ideally, an entity interested in acquiring a company should seek approval from the target company’s Board of Directors. The difference between a hostile and a friendly takeover is that, in a friendly takeover, the target company’s board of directors approve of the transaction and recommend shareholders vote in favor of the deal.

Defenses against a hostile takeover

These defense mechanisms can be preemptive or reactive, depending on how prepared the company is for the possibility of a hostile bid.

Poison pill is one of the most common defenses against a hostile takeover. Officially known as a “shareholder rights plan,” the poison pill allows existing shareholders to purchase additional shares at a discount, diluting the ownership interest of the acquiring company. The goal is to make it prohibitively expensive for the acquirer to complete the takeover.

A golden parachute is another defense strategy, which involves providing lucrative compensation packages (bonuses, severance pay, stock options, etc.) to key executives in the event they are terminated as a result of the takeover. This creates a financial disincentive for the acquiring company, as it would need to pay out these large sums upon completing the takeover.

In a Crown jewel defense, the target company sells or threatens to sell its most valuable assets—its “crown jewels”—if the takeover is completed. This reduces the attractiveness of the company to the acquirer, as the most desirable assets would no longer be part of the deal.

The Pac-Man defenses a more aggressive strategy in which the target company turns the tables by attempting to buy shares of the acquiring company, effectively launching a counter-takeover. While rare, this defense can deter hostile bids by making the takeover battle more costly and complex.

A White-Knight defense involves the target company seeking out a more favorable acquirer, or “white knight,” to make a friendly takeover bid. This allows the target company to avoid the hostile acquirer while still securing the benefits of a merger or acquisition.

EXAMPLE: Sanofi-Aventis and Genzyme Corp. Year: 2011 Deal value: $20.1 billion Industry: Pharmaceutical

The hostile takeover between Sanofi-Aventis and Genzyme Corp. occurred in 2010 when Sanofi, a French pharmaceutical company, wanted to buy Genzyme, a US biotech firm specializing in rare diseases. Genzyme resisted the offer, leading to conflict. Sanofi started a public campaign to pressure Genzyme’s shareholders into selling.

After months of negotiations, the two companies reached a deal in 2011. Sanofi agreed to pay $74 per share, with additional payments tied to Genzyme’s future performance, bringing the total deal value to around $20.1 billion. This acquisition allowed Sanofi to expand into the lucrative market for rare disease treatment.

MORE: https://www.law.cornell.edu/wex/hostile_takeover

COMMENTS APPRECIATED

Refer and Subscribe

***

Filed under: Career Development, Drugs and Pharma, Ethics, Experts Invited, Financial Advisor Listings, Financial Planning, Funding Basics, Glossary Terms, Health Economics, Health Law & Policy, Healthcare Finance, Investing, Marcinko Associates, Touring with Marcinko | Tagged: Aventis, CFI, crown jewel defense, friendly takeover, Genzyme, golden parachute, healthcare, hostile takeover, Marcinko, medical, pac-man defense, pharma, pharmaceutical, poison pill, research, Sanofi, trends, USA, white knight | Leave a comment »

DAILY UPDATE: PBMs and Healthcare A.I. as All Major Market Indexes Drop

Posted on December 18, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?

REFER A COLLEAGUE: MarcinkoAdvisors@msn.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

Your Referral Count -0-

Stat: 97%. That’s how many healthcare leaders think A.I. will become important in healthcare over the next five years.

***

Pharmacy benefit managers (PBMs) are once again under pressure from federal leaders. A group of Democratic and Republican congresspeople proposed legislation that would attempt to prevent pharmacies from also owning PBMs. The three largest PBMs—CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum Rx—currently operate pharmacies and administer more than 80% of the prescriptions in the US, and officials have linked this practice to drug price increases.

CITE: https://tinyurl.com/2h47urt5

US stocks fell across the board on Tuesday, with the Dow logging its biggest losing streak in 46 years. The Dow Jones Industrial Average (^DJI) finished the session down roughly 0.6%, registering its ninth straight day of losses. The last 9-day losing streak for the Dow was Feb. 1978. Prior to that, the index suffered an 11-day losing streak in 1974 and another in 1971.

The other major indexes dropped in tandem on Tuesday, with the benchmark S&P 500 (^GSPC) falling around 0.4% and the NASDAQ Composite (^IXIC) losing about 0.3% after the tech-heavy index closed at a record high on Monday.

CITE: https://tinyurl.com/tj8smmes

Visualize: How private equity tangled banks in a web of debt, from the Financial Times.

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@msn.com

Thank You

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

Filed under: "Ask-an-Advisor", "Doctors Only", Accounting, Drugs and Pharma, Ethics, Financial Planning, Funding Basics, Glossary Terms, Health Economics, Health Insurance, Health Law & Policy, Healthcare Finance, Information Technology, Investing, Marcinko Associates, Recommended Books, Sponsors | Tagged: AI, artificial intelligence, Artificial Intelligence Medicine, Caremark, Cigna, CVs, DJIA, DOW, drug prices, health, healthcare, Healthcare AI, Marcinko, NASDAQ, Optum Rx, PBM, PBMs, pharma, Pharmacy Benefits Managers, S&P 500, Technology, textbooks, TNX, UnitedHealth, VIX, WSJ | Leave a comment »

DAILY UPDATE: Pfizer Down While Stock Markets Ignite

Posted on October 9, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?

REFER A COLLEAGUE: MarcinkoAdvisors@msn.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

Your Referral Count -0-

Activist investor takes $1 billion stake in Pfizer. The firm Starboard Value has amassed a stake in the pharma giant, which has struggled after reaching new heights during the pandemic, in hopes of turning the company around.

CITE: https://www.r2library.com/Resource

What’s up

If you can’t beat ‘em, join ‘em: WW International, aka WeightWatchers, soared 46.95% after the company announced it will begin offering GLP-1 weight-loss drugs.
Nvidia rose 4.05% after the Foxconn CEO told CNBC that AI demand is still incredibly strong.
Trump Technology & Media Group soared 18.54% after Tesla CEO Elon Musk appeared alongside the former president at a rally in Pennsylvania over the weekend.
Palantir popped 6.58% after the CTO of the data analytics firm appeared on CNBC and told everyone that his company is making mad money.
Welcome to the club: S&P Global announced that DocuSign is replacing MDU Resources Group in the S&P MidCap 400 index, while MDU is moving to the S&P SmallCap 600 index. Docusign rose 6.55% on the news, while MDU gained 2.44%.
Humana finally caught a break when a Bernstein analyst upgraded the stock today, writing that the health insurer has been hurt enough. Shares rose 2.92%.

What’s down

What goes up must come down: Chinese stocks, which have enjoyed an impressive rally recently, came tumbling back to Earth today after the country’s state planner didn’t announce any new stimulus measures. Bilibili fell 12.93%, JD.com lost 7.52%, Alibaba sold off 6.67%, and Nio dropped 8.10%.
Today’s oil selloff pummeled energy stocks: Valero Energy lost 5.31%, while Marathon Petroleum stumbled 7.66%.
Sphere Entertainment dropped 2.84% on the news that its CFO is leaving the company.
Super Micro Computer gave back 5.01% after its rally yesterday as investors pocketed their profits.

CITE: https://tinyurl.com/2h47urt5

Here’s where the major benchmarks ended:

The SPX rose 55.19 points (0.97%) to 5,751.15; the Dow Jones Industrial Average^® ($DJI) added 126.13 points (0.30%) to 42,080.37; and the NASDAQ Composite^® ($COMP) gained 259.01 points (1.45%) to 18,182.92.
The 10-year Treasury note yield (TNX) rose one basis point to 4.03%.
The CBOE Volatility Index^® (VIX) sank to 21.24, still above its long-term average.

CITE: https://tinyurl.com/tj8smmes

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@msn.com

Thank You

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

Filed under: Drugs and Pharma, Experts Invited, Information Technology, Investing, Marcinko Associates, Recommended Books, Sponsors | Tagged: DJIA, DOW, finance, Marcinko, NASA, NASDAQ, Pfizer, pharma, S&P 500, Starboard Value, stock market, stocks, textbooks, TNX, VIX, WSJ | Leave a comment »

AbbVie: The Economic Recession Index?

Posted on September 4, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

The BOTOX Predictor Index?

By Staff Reporters

***

***

It’s looking more than likely that we’ll see a recession in the next year, and Americans are preparing themselves by taking steps like delaying major purchases, allocating more of their income to savings, and staying in jobs they don’t love. Another thing they’re not doing? Getting Botox. And that’s bad news for AbbVie; according to Neal Freyman of Morning Brew.

AbbVie, one of the biggest drug manufacturers in the US, brought Botox into its medical aesthetics portfolio—which also includes the popular dermal filler Juvederm—in 2020, when it bought rival drug maker Allergan for $63 billion. AbbVie CEO Richard Gonzalez said during the company’s Oct. 28th earnings call that the company expects the aesthetics business to take a hard hit in 2024 as recession fears cause consumers to be more cautious with their spending.

“Based on all the data we’ve been observing, especially in the US, with both the consumer-confidence index and real personal consumption expenditures trending down and continued high inflation, these factors are putting pressure on consumer’s discretionary spending,” Gonzalez said.

AbbVie lowered its 2022-23 full-year forecast for its aesthetics business by $600 million, down to $5.3 billion. After the earnings call, AbbVie’s stock fell 4.3%. Through the third quarter of 2022, Botox has brought in $1.97 billion for the aesthetics business. The third quarter saw $637 million in cosmetic Botox sales, down from an expected $640 million. Gonzalez said he doesn’t think the hit on sales will last long, though.

***

***

“As consumer confidence improves, we would once again expect the market growth to accelerate. Our aesthetics portfolio experienced a rapid and sustained recovery following the 2008, 2009 recession,” Gonzalez said.

But Botox also faces a new competitor, called Daxxify, which just got FDA approval in September. Made by Revance Therapeutics, the drug may last longer: In clinical trials, Daxxify injections lasted six to nine months, while Botox injections typically last three months.

***

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Doctors Only", Alternative Investments, Career Development, Drugs and Pharma, Health Economics, Health Insurance, Healthcare Finance, Investing | Tagged: AbbVie, AbbVie: The Economic Recession?, Allergan, botex predictor index, Botox, economic recession, FDA, Juvederm, Morning Brew, pharma | 1 Comment »

CLINICAL DRUG TRIALS: Safer?

Posted on September 3, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

A new device could make drug trials safer

Northwestern University scientists have developed a smaller-than-a-shoebox contraption that can simulate how the human body reacts to various diseases or medications. This technology could be used as an additional fail-safe check in clinical trials between the animal and human testing stages. The device makes it easier for scientists to understand how diseases and drugs affect the body because it can simulate the effects of up to eight different organ tissue samples at once for as long as 28 days.

It’s a big step up from current drug-simulating lab systems, which can only accommodate two tissue cultures that don’t last for very long.

COMMENTS APPRECIATED

Thank You

***

Filed under: Drugs and Pharma, Ethics | Tagged: clinical drug trials, clinical trials, drug trials, Drugs, pharma, phase 4 | Leave a comment »

PHYSICIAN PAYMENTS: Drug and Device Makers

Posted on April 10, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

Physicians Received $12 Billion from Drug & Device Makers in Less Than 10 Years

A review of the federal Open Payments database found that the pharmaceutical and medical device industry paid physicians $12.1 billion over nearly a decade. Almost two thirds of eligible physicians — 826,313 doctors — received a payment from a drug or device maker from 2013 to 2022, according to a study published online in JAMA on March 28th. Overall, the median payment was $48 per physician.

CITE: https://www.r2library.com/Resource

Orthopedists received the largest amount of payments in aggregate, $1.3 billion, followed by neurologists and psychiatrists at $1.2 billion, and cardiologists at $1.29 billion. To find out what any physician was paid, click here.

Source: Alicia Ault, MD Edge [4/3/24]

COMMENTS APPRECIATED

Subscribe Today

***

Filed under: "Doctors Only", Accounting, Career Development, Drugs and Pharma, Ethics, Experts Invited, Risk Management | Tagged: alicia ault, AMA, CMS, CMS payments doctors, CMS payments physicians, DME, Drugs, JAMA, MD Edge, Medical Devices, Open Payments, pharma | Leave a comment »

DAILY UPDATE: Kroger Selling Pharma Business as Nvidia and Stock Markets Rise

Posted on March 21, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

CHERRY BLOSSOM FESTIVAL, DC.

***

***

KROGER, the supermarket chain said it expects to close the sale of its specialty pharmacy business during the second half of 2024. Kroger said it is planning to sell its speciality pharmacy business to pharmacy benefit manager CarelonRx, a subsidiary of Elevance Health, the company just reported.

CITE: https://www.r2library.com/Resource

***

Nvidia continues its bid for world domination with the announcement of its new B200 “Blackwell” chip. The Blackwell is 2.5 times more powerful than the “Hopper” chip which helped it become a $2 trillion company. (Bloomberg)

Here’s where the major benchmarks ended:

The S&P 500 index added 46.11 points (0.9%) to 5,224.62; the Dow Jones Industrial Average gained 401.37 points (1%) to 39,512.13; the NASDAQ Composite rose 202.62 points (1.3%) to 16,369.41.
The 10-year Treasury note yield slid two basis points to 4.27%.
The CBOE Volatility Index^®(VIX) fell 0.77 to 13.06.

Health care was the biggest loser among the S&P 500 sectors. Energy was also lower after crude oil prices sank on the heels of weekly inventory data. Brent Crude Oil (/BZ) futures, the global benchmark, dropped 1.6% on the heels of five days of gains.

COMMENTS APPRECIATED

Thank You

***

Filed under: "Ask-an-Advisor", Breaking News, Drugs and Pharma, Ethics, Experts Invited, Financial Planning, Health Economics, Health Insurance, Healthcare Finance, Information Technology, Investing | Tagged: Blackwell chip, brent, CarelonRx, CBOE, crude oil, DJIA, DOW, Drugs, Elevance Health, Hopper chip, Kroger, medical debt, NASDAQ, Nvidia, pharma, prescriptions, Rx, S&P 500, specialty pharma, VIX | Leave a comment »

DAILY UPDATE: Inflation Upticks as Big Pharma Blocks Medicare Price Negotiations and Stocks Soar with Nvidia and Oracle!

Posted on March 13, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

Big pharma sues over California drug price law

***

Pharmaceutical companies have filed a slew of suits around the country to get federal judges to invalidate a government program aimed at lowering drug costs for seniors by allowing Medicare to negotiate prices, as is the norm in many other countries, according to the Washington Post. The companies argue it’s unconstitutional and would inhibit their ability to develop new treatments.

CITE: https://www.r2library.com/Resource

The Federal Reserve is looking for steady, reliable signs that inflation is simmering down before it cuts interest rates this year. So far, 2024 has not delivered. Data released by the Bureau of Labor Statistics on Tuesday showed prices rose 3.2 percent over last year, slightly outpacing forecasts of 3.1 percent. Prices also rose 0.4 percent in February over the previous month — in line with expectations, but still hotter than economists would like to discern.

Stocks swung up on Tuesday as investors shrugged off a middling inflation report and looked ahead to next week’s Fed meeting. Meanwhile, Oracle went sky-high, posting its best day since 2021 after demand for AI prompted a huge increase in sales for its cloud computing business.

Here’s where the major benchmarks ended:

The S&P 500^® index (SPX) gained 57.33 points (1.1%) to 5,175.27; the Dow Jones Industrial Average^® ($DJI) added 235.83 points (0.6%) to 39,005.49; the NASDAQ Composite^® (COMP) climbed 246.36 points (1.5%) to 16,265.64.
The 10-year Treasury note yield (TNX) rose about 5 basis points to 4.155%.
The CBOE Volatility Index^® (VIX) fell 1.38 to 13.84.

Chip makers’ bounce-back helped boost the Philadelphia Semiconductor Index (SOX) more than 2%, as it recovered part of a 5% drop the previous two trading days. Industry leader Nvidia (NVDA) jumped over 7%. Consumer discretionary and communications services shares were also among the strongest areas. Regional banks and real estate were among the weakest sectors as the CPI data spurred an upturn in Treasury yields.

COMMENTS APPRECIATED

Thank You

***

Filed under: "Ask-an-Advisor", Drugs and Pharma, Ethics, Experts Invited, Financial Planning, Health Economics, Health Insurance, Healthcare Finance, Investing, Managed Care | Tagged: Big Pharma, BLS, Bureau Labor Statistics, CBOE, cost living, DJIA, Drugs, inflation, inflation upticks, medicare drug prices, NASDAQ, Nvidia, NYC, oracle, pharma, pharmaceutical companies, pharmaceutical pricing, S&P 500, SOX, SPX, TNX, VIX | Leave a comment »

DAILY UPDATE: Consumer Spending Down While CVS Earnings Up

Posted on February 20, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

To See What’s Next For Consumer Spending, Take a Closer Look at High ...

Stat: 0.8%. That’s how much consumer spending fell in January 204—a much bigger dip than expected (CNBC).

CITE: https://www.r2library.com/Resource

CVS reported strong results for its healthcare segment in 2023, showing a 10.2% increase in revenue compared to the prior year. Still, executives lowered the segment’s 2024 guidance in anticipation of rising medical costs, according to earnings released this month.

Finally, the US stock market reopens today after the long weekend, and everyone’s still talking about the Magnificent Seven. That’s because, according to a new report from Deutsche Bank, profits at these seven tech giants are greater than the profits of all publicly traded companies in nearly every G20 country. And in terms of market value, they’d be the second-largest national stock exchange in the world. Goldman Sachs sees this party lasting all night: It raised its 2024 target for the S&P 500 for the second time.

COMMENTS APPRECIATED

Thank You

***

Filed under: "Ask-an-Advisor", Drugs and Pharma, Experts Invited, Funding Basics, Information Technology, Investing, LifeStyle | Tagged: CNBC, consumer spending, consumer spending down, CVs, CVS Health, Deautsche Bank, Drugs, G20, Goldman Sachs, Magnificent 7, magnificent seven, PBM, pharma, pharmacy, Pharmacy Benefit Mangers, stock markets | Leave a comment »

DAILY UPDATE: Name Brand Drug Prices Up as Corporate Earnings Week Awaits

Posted on February 5, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

As the federal government seeks to rein in drug prices, pharmaceutical companies this year have been raising prices on hundreds of name-brand drugs. A new analysis by the drug research firm 46brooklyn Research found that companies increased prices on 910 branded drugs in January, although the median increase was 4.7% – the lowest drug inflation rate in more than a decade, the analysis shows.

CITE: https://www.r2library.com/Resource

Whether you’re into (McDonald’s), (Disney), (Ford), (Chipotle), or paying extra for medicine (Eli Lilly), there’s an earnings report for you this week. A strong earnings season so far has helped push the major stock indexes to four straight weekly gains.

And, while Meta’s historic stock-pop hosted the headlines last week, Nvidia has quietly put together a phenomenal start to 2024. The chip-making giant added nearly $300 billion in market value in January, its biggest monthly gain ever. That’s one reason the S&P 500 is kicking off the week at a record high.

COMMENTS APPRECIATED

Thank You

***

Filed under: Breaking News, Drugs and Pharma, Ethics, Experts Invited, Health Economics, Health Insurance, Healthcare Finance, Investing | Tagged: branded drugs, CBOE, Chipotle, Disney, DJIA, drug prices, Drugs, Eli Lily, FB, Ford, Meta, name brand, NSDAQ, Nvidia, pharma, S&P 500, VIX | Leave a comment »

PODCAST: Doctors Subconsciously Influenced By Pharmaceutical Companies?

Posted on January 26, 2024 by Dr. David Edward Marcinko MBA MEd CMP™

Dr. Eric Bricker MD

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Doctors Only", Career Development, Drugs and Pharma, Experts Invited, Industry Indignation Index, Op-Editorials, Videos | Tagged: Drugs, Eric Bricker, pharma, pharmaceutical companies, pharmaceuticals, prescriptions, Rx | Leave a comment »

PODCAST: How PBMs Work -OR- Don’t Work?

Posted on November 15, 2023 by Dr. David Edward Marcinko MBA MEd CMP™

“PRIOR AUTHORIZATION“

By Eric Bricker MD

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Doctors Only", Career Development, Drugs and Pharma, Ethics, Experts Invited, Videos | Tagged: Drugs, Eric Bricker, ori-authorization, PBM, PBMs, pharma, pre-authorization, RPh | Leave a comment »

Happy Birthday Florence Nightingale [203rd]

Posted on May 12, 2023 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

Happy 203rd birthday to Florence Nightingale, the founder of modern nursing. She rose to fame during the Crimean War, when her hygiene standards substantially reduced the mortality rate at army hospitals. The healthcare industry still relies on some of her ideas, such as using data as a tool to improve hospital care. The “lady with the lamp” is still lighting the path forward.

***

Other Health Care Stories

COMMENTS APPRECIATED

Thank You

***

Filed under: "Doctors Only", Accounting, Breaking News, Drugs and Pharma, Ethics, Health Economics, Health Insurance, Health Law & Policy, Healthcare Finance, Risk Management | Tagged: AI, covid, Crimean war, Florence Nightingale, pharma | Leave a comment »

DAILY UPDATE: Inflation, Public Health and the Markets

Posted on May 11, 2023 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

Because the inflation data came in roughly as expected, Wall Street sees the door still open for the Federal Reserve to leave interest rates alone at its next meeting in June. That would be the first time it hasn’t raised rates at a meeting in more than a year, and a pause would offer some breathing room for the economy and financial markets.

CITE: https://www.r2library.com/Resource

***

Today is the last day of the US Covid-19 public health emergency, which has been in place since Jan. 31st, 2020. With it comes the end of certain Covid-era rules, though some telehealth protections have been extended through the end of 2024. Here’s to all the medical professionals who got us through, and a remembrance for the millions who lost their lives to Covid.

***

Brightline, a California-based mental health startup, laid off 20% of its staff this week following a data breach.
North Carolina is the latest state to consider changes to the prior authorization process that advocates say delays care.
A board member at Geisinger claims that consolidation prompted the healthcare provider to sell to Kaiser Permanente.
Texas Gov. Greg Abbott said the state should address mental health issues in the wake of a shopping mall mass shooting, but did not call for gun control reform.

Pharma companies lean on AI for better innovation, efficiency AstraZeneca has big R&D goals to mitigate future declines in Covid-related sales Say goodbye to trypanophobia—this biotech is trying to turn injectable drugs into pills

***

Finally, here is where the major benchmarks ended yesterday:

The S&P 500 Index was up 18.47 points (0.5%) at 4137.64; the Dow Jones industrial average was down 30.48 (0.1%) at 33,531.33; the NASDAQ Composite was up 126.89 (1.0%) at 12,306.44.
The 10-year Treasury yield was down about 8 basis points at 3.441%.
CBOE’s Volatility Index was down 0.80 at 16.91.

Oilfield services providers and other energy companies were among the laggards Wednesday, pressured by a more-than 1% drop in WTI crude oil futures.

Financial sector stocks struggling to escape the effects of the bank volatility earlier this spring helped push the KWB Regional Bank Index back near a 2½-year low reached last week.

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Ask-an-Advisor", Alerts Sign-Up, Alternative Investments, Drugs and Pharma, Health Economics, iMBA, Inc., Information Technology, Investing, LifeStyle | Tagged: AI, Brightline, covid, DJIA, DOW, Federal Reserve, FOMA, gold, HIT, inflation, KWB, mental health, NASDAQ, oil, pharma, S&P 500, Tele-Health, Treasury yields, volatility, WTI | Leave a comment »

DAILY UPDATE: Big Pharma Earnings, Covid, RSV Vaccine, FOMC and the Markets

Posted on May 4, 2023 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

MAY THE FOURTH BE WITH YOU

***

***

Many pharma companies reported earnings in the last week, and the common thread is crashing Covid-related sales.

For example, AstraZeneca’s Covid medication sales dropped $1.5b in Q1, Merck’s Covid antiviral sales fell 88% from the same quarter in 2022, and Roche’s diagnostics division sales fell 28% from Q1 2022, thanks to low Covid-test demand. Clearly, pharma companies have to figure out how to pivot their strategies in a post-Covid world.

CITE: https://www.r2library.com/Resource

***

The CDC will not continue to track Covid-19 community spread as the country enters the endemic stage of the pandemic.

***

The Food and Drug Administration approved Wednesday the first-ever vaccine to combat severe respiratory syncytial virus, or RSV. Arexvy, the new vaccine developed by GlaxoSmithKline, was approved for adults 60 and older and was 82% effective at preventing lower respiratory tract illness caused by RSV, according to trial data. It was also 94% effective in those who had at least one underlying medical condition.

***

The Federal Reserve voted unanimously to raise interest rates by a quarter point yesterday, the tenth rate hike since the central bank started its battle against inflation last March. The move comes amid ongoing fragility in the banking sector triggered partly by higher interest rates, and following the collapse of three regional banks. Markets had anticipated the rate hike, and remained fairly muted after the Fed’s announcement.

***

Finally, here’s where the major indexes ended up:

The S&P 500^® Index was down 28.83 points at 4090.75; the Dow Jones industrial average was down 270.29 (0.8%) at 33,414.24; the NASDAQ Composite was down 55.18 (0.5%) at 12,025.33.
The 10-year Treasury yield was down about 7 basis points at 3.367%.
CBOE’s Volatility Index was up 0.52 at 18.30.

Energy companies were among the market’s weakest performers as crude oil continued a recent decline, with WTI crude futures falling more than 4% under $70 a barrel—a nearly six-week low.

Semiconductor and financial shares were also weak. The U.S. dollar index dropped sharply in the wake of the Fed announcement before rebounding.

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

***

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Ask-an-Advisor", Alerts Sign-Up, Drugs and Pharma, Health Economics, Health Insurance, Investing | Tagged: Arexvy, Big Pharma, covid, DJIA, DOW, FDA, Federal Reserve, FOMC, Food Drug Administration, GlaxoSmithKline, gold, inflation, interest rates, Merck, NASDAQ, oil, pharma, Respiratory syncytial virus, Roche, RSV, Russell 2000, S&P 500, Treasury yields | Leave a comment »

DRUGS: Use and Abuse Epidemiology Information

Posted on February 24, 2023 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

“The staggering increase in methamphetamine-related deaths in the United States is largely now driven by the co-involvement of street opioids.”—Rachel Hoopsick, an assistant professor of epidemiology at the University of Illinois at Urbana-Champaign and lead researcher on a 20-year study (US News and World Report)

***

How 3 companies came to dominate the PBM market

MORE: https://medicalexecutivepost.com/2022/09/21/podcast-pbm-money-flow-explained/

***

More docs than ever use health IT for opioid prescribing

LINK: https://www.amazon.com/Dictionary-Health-Information-Technology-Security/dp/0826149952/ref=sr_1_5?ie=UTF8&s=books&qid=1254413315&sr=1-5

***

Drug Econometrics

LINK: https://medicalexecutivepost.com/2016/11/06/are-soaring-health-care-costs-hurting-the-u-s-economy/

COMMENTS APPRECIATED

CITE: https://www.r2library.com/Resource/Title/082610254

Thank You

***

Filed under: Breaking News, Career Development, Drugs and Pharma, Experts Invited, Information Technology, Research & Development, Risk Management | Tagged: Drugs, OPIOID CRISIS?, opioids, PBM, pharma, Rachel Hoopsick | Leave a comment »

PODCAST: Doctor’s Don’t Disclose Conflicts of Interest

Posted on December 13, 2022 by Dr. David Edward Marcinko MBA MEd CMP™

C.O.I.

By Eric Bricker MD

***

MORE: https://medicalexecutivepost.com/2022/10/05/video-on-doctors-money-and-conflicts-of-interest/

***

COMMENTS APPRECIATED

Thank You

CITE: https://www.r2library.com/Resource/Title/082610254

***

Product Details

ORDER: https://www.amazon.com/Business-Medical-Practice-Transformational-Doctors/dp/0826105750/ref=sr_1_9?ie=UTF8&qid=1448163039&sr=8-9&keywords=david+marcinko

***

Filed under: "Doctors Only", Drugs and Pharma, Ethics, Health Economics, Health Insurance, Professional Liability | Tagged: COI, Conflicts of Interest, Don't Disclose Conflicts of Interest, Drugs, Eric Bricker MD, pharma, pharmaceuticals | Leave a comment »

PHARMA: Will Americans Finally See Drug Prices Decrease?

Posted on November 4, 2022 by Dr. David Edward Marcinko MBA MEd CMP™

By Health Capital Consultants, LLC

***

***

According to the White House, “Americans pay two to three times as much as people in other countries for prescription drugs, and one in four Americans who take prescription drugs struggle to afford their medications. Nearly 3 in 10 American adults who take prescription drugs say that they have skipped doses, cut pills in half, or not filled prescriptions due to cost.” In an effort to combat this growing crisis, both the federal government and private companies have taken a number of steps over the past year aiming to lower drug prices. This Health Capital Topics article will review those actions and the potential unintended consequences of these actions.

(Read more…)

COMMENTS APPRECIATED

Thank You

CITE: https://www.r2library.com/Resource/Title/082610254

ORDER: https://www.amazon.com/Hospitals-Healthcare-Organizations-Management-Operational/dp/1439879907/ref=sr_1_4?s=books&ie=UTF8&qid=1334193619&sr=1-4

***

Filed under: "Doctors Only", Drugs and Pharma, Experts Invited, Glossary Terms, Health Economics, Health Insurance | Tagged: drug prices, Drugs, Health Capital Consultants LLC, PBM, pharma, pharmacy, Pharmacy Benefits Managers, Will Americans Finally See Drug Prices Decrease? | Leave a comment »

CVS, Walgreens and Walmart: Opioid Settlement

Posted on November 3, 2022 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

CVS, Walgreens, and Walmart agree to pay $13 billion over opioids

The pharmacy chains have reached a tentative deal to settle thousands of lawsuits brought by state and local governments that accuse them of contributing to the opioid epidemic.

If the deal goes through, CVS and Walgreens will each cough up around $5 billion, and Walmart will reportedly be on the hook for $3 billion.

***

COMMENTS APPRECIATED

Thank You

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

***

Filed under: Breaking News, Drugs and Pharma, Ethics, Health Insurance, Risk Management | Tagged: CVs, Drugs, opioids, pharma, pharmaceuticals, Walgreen's, Walmart | Leave a comment »

Supreme Court Hears Oral Arguments on 340B Drug Pricing Cuts

Posted on January 19, 2022 by Dr. David Edward Marcinko MBA MEd CMP™

BY HEALTH CAPITAL CONSULTANTS, LLC

***

Supreme Court Hears Oral Arguments on 340B Cuts

On November 30, 2021, the U.S. Supreme Court heard oral arguments regarding the challenges arising from the cuts made by the Centers of Medicare & Medicaid Services (CMS) to the 340B Drug Pricing Program.

The 340B Drug Pricing Program allows hospitals and clinics that treat low-income, medically underserved patients to purchase certain “specified covered outpatient drugs” at discounted prices (applying a ceiling to what drug manufacturers may charge certain healthcare facilities) – 25% to 50% of what providers would typically pay – and then receive reimbursement pursuant to the rates set forth in the Outpatient Prospective Payment System (OPPS) at the same rate as all other providers. (Read more…)

***

HEALTH ECONOMICS CITE: https://www.r2library.com/Resource/Title/0826102549

PODCAST: https://medicalexecutivepost.com/2021/08/27/podcast-hospital-340-b-drug-programs/

***

Filed under: Accounting, Breaking News, Drugs and Pharma, Experts Invited, Videos | Tagged: 340-B Drug Program, Centers of Medicare & Medicaid Services, CMS, CMS drug pricing program, Drugs, Health Capital Consultants LLC, Health Economics, OPPS, Outpatient Prospective Payment System, pharma, pharmacy | 1 Comment »

PODCAST: Prescription Patient Assistance Programs

Posted on January 11, 2022 by Dr. David Edward Marcinko MBA MEd CMP™

BY ERIC BRICKER MD

With 43 Million Americans Having Lost Their Job at Some Point During the Pandemic and About 1/2 Those Jobs Providing Health Insurance… the 1st Group–People Who Do Not Have Health Insurance–Needs to Be Aware of How These Programs Work.

In this Video You Will Learn the Patient Assistance Program Process for:

1) 2 of the Most Common Types of Insulin

2) The Highest-Revenue Medication in America: Humira

**Note: At the Time of the Video’s Recording, the Unemployment Rate in the US was 15%. As of November 2021, the Unemployment Rate is 4.2%.

***

COMMENTS APPRECIATED

Subscribe to the Medical Executive-Post

***

CITE: https://www.r2library.com/Resource/Title/082610254

***

Filed under: Drugs and Pharma, Ethics, Experts Invited, Glossary Terms, Health Economics, Health Insurance, Healthcare Finance, iMBA, Inc., Videos | Tagged: Eric Bricker MD, Health Insurance, humira, insulin, Patient Assistance Programs, PBMs, pharma, pharmaceuticals, Prescription Patient Assistance Programs | 1 Comment »

PODCAST: The 10 Top Technology Trends Shaping the Future of the Pharma

Posted on October 8, 2021 by Dr. David Edward Marcinko MBA MEd CMP™

THE CULTURAL SHIFT

Dr. Bertalan Meskó, MD

The pharma industry has taken a big swung into digital transformation. All participants invest in digital health topics.

But as with all trending issues, and there is a lot of fuss that is hard to see through. As the medical community increasingly acknowledges the importance of digital health, the cultural shift we so often talk about is still a way to go. To change that, the first step is always getting to know what’s coming.

In this article, with podcast, Bert collected the trends changing the pharmaceutical industry.

ESSAY AND PODCAST: https://medicalfuturist.com/top-10-trends-shaping-future-pharma/?utm_source=The%20Medical%20Futurist%20Newsletter&utm_campaign=3a501b1978-EMAIL_CAMPAIGN_2021_09_05_Resend&utm_medium=email&utm_term=0_efd6a3cd08-3a501b1978-399696053&mc_cid=3a501b1978&mc_eid=40fee31c25#

YOUR THOUGHTS AND COMMENTS ARE APPRECIATED.

Thank You

***

****

Click to access foreword-mata.pdf

Filed under: "Doctors Only", Drugs and Pharma, Experts Invited, Information Technology | Tagged: Dr. Bertalan Meskó, Drugs, medical digital transformation, pharma, pharma future, pharma trends | Leave a comment »

PODCASTS: FDA Pharmaceutical Industry Ties

Posted on September 15, 2021 by Dr. David Edward Marcinko MBA MEd CMP™

CONFLICTS OF INTEREST?

The New York Times Had an Excellent Article on the FDA on September 2, 2021.

The Article Described How the FDA Began Receiving Funding from the Pharmaceutical Industry Itself to Pay for FDA Employee Salaries in 1992–a Potential Conflict-of-Interest. Subsequently, a Study Found that 1/3 of Drugs Approved by the FDA Were Found to Have Safety Problems from 2000 -2010. Another Potential Conflict-of-Interest is Number of FDA Regulators Who Leave Their Positions to Take High-Paying Jobs at Pharmaceutical Companies.

By Eric Bricker MD

FDA rescinds emergency authorization for COVID-19 antibody treatment bamlanivimab | TheHill

PODCAST:

***

YOUR COMMENTS ARE APPRECIATED.

Thank You

****

***

Filed under: "Doctors Only", Drugs and Pharma, Ethics, Experts Invited, Op-Editorials, Videos | Tagged: Big Pharma, DEA, Drugs, Eric Bricker MD, FDA, NYT, pharma, pharma conflicts, pharmaceutical industry | Leave a comment »

The PBMI Innovation Challenge

Posted on August 6, 2021 by Dr. David Edward Marcinko MBA MEd CMP™

There’s still time!

Submit your innovative solution in patient health management to the Pharmacy Benefit Management Institute (PBMI) Innovation Challenge by August 6, 2021 for the chance to be among one of the 5 finalists selected to pitch their ideas before a panel of judges at the PBMI 2021 Annual Meeting!

Be sure to submit your idea by August 6, 2021 for the chance to be featured in an upcoming issue of Managed Healthcare Executive with a full-year integrated marketing program valued at over $100K, in addition to formal acknowledgment at this year’s PBMI Conference.

REGISTER: https://events.pbmi.com/event/31593a7e-d661-4ea5-abf2-5aa6473e1a14/summary

***

Filed under: Drugs and Pharma | Tagged: Drugs, PBM, pharma, Pharmacy Benefit Mangers | 1 Comment »

Peri-Operative MEs and ADEs

Posted on December 14, 2015 by Dr. David Edward Marcinko MBA MEd CMP™

One in Twenty [1/20]

By http://www.MCOL.com

***

ImageProxy

***

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
ADVISORS: www.CertifiedMedicalPlanner.org
FINANCE: Financial Planning for Physicians and Advisors
INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
Dictionary of Health Economics and Finance
Dictionary of Health Information Technology and Security
Dictionary of Health Insurance and Managed Care

[HEALTH INSURANCE, MANAGED CARE, ECONOMICS, FINANCE AND HEALTH INFORMATION TECHNOLOGY COMPANION DICTIONARY SET]

[Mike Stahl PhD MBA] *** [Foreword Dr.Mata MD CIS] *** [Dr. Getzen PhD]

***

Filed under: Drugs and Pharma, Quality Initiatives | Tagged: ADEs, Drugs, MEs, pharma, www.MCOL.com | 1 Comment »

National Health Expenditure Growth

Posted on January 16, 2014 by Dr. David Edward Marcinko MBA MEd CMP™

A Report from the Office of the Actuary

Source: Centers for Medicare & Medicaid Services

According to the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary, overall national health expenditures grew at an annual rate of 3.7 percent in 2012, marking the fourth consecutive year of low growth. Health spending as a share of gross domestic product fell slightly from 17.3 percent in 2011 to 17.2 percent in 2012.

Private Insurance

Private health insurance spending growth remained low. Private health insurance spending continued to grow at a low rate, increasing 3.2 percent in 2012 compared to 3.4 percent growth in 2011. Medicare spending growth continued to be low. Despite a large uptick in Medicare enrollment, Medicare spending growth slowed slightly in 2012, increasing by 4.8 percent compared to 5.0 percent growth in 2011.

The Totals for MC/MD

Total Medicare spending per enrollee grew by only 0.7 percent in 2012. Medicaid spending continued to grow at a historically low rate. Total Medicaid spending grew 3.3 percent in 2012. While an increase over 2011, this increase still represents historically low overall growth rates tied to improved economic conditions, as well as efforts by states to control costs.

Rx Drugs

Prescription drug spending growth was low. Retail prescription drug spending slowed in 2012, growing only 0.4 percent as the result of numerous drugs losing their patent protection, leading to increased sales of lower-cost generics. Nursing home spending growth slowed.

Assessment

Spending for freestanding nursing care facilities and continuing care retirement communities increased by only 1.6 percent in 2012, down from 4.3 percent growth in 2011, due to a one-time Medicare rate adjustment for skilled nursing facilities.

Conclusion

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

DICTIONARIES: http://www.springerpub.com/Search/marcinko
PHYSICIANS: www.MedicalBusinessAdvisors.com
PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
BLOG: www.MedicalExecutivePost.com
FINANCE: Financial Planning for Physicians and Advisors
INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors

Filed under: Drugs and Pharma, Health Economics, Health Insurance | Tagged: Centers for Medicare & Medicaid Services, CMS, Drugs, National Health Expenditure Growth, pharma, Retail prescription drug spending | 1 Comment »

Doctors on Drugs

Posted on June 23, 2012 by Dr. David Edward Marcinko MBA MEd CMP™

Profitable Prescriptions?

Increasing in costs each year, prescription pills are one of the most profitable and dominating industries in the nation, with annual sales in the hundreds of billions. Prescribed medications constitute a significant bulk of work that medical coders must transcribe.

The Rx Pill Industry

Shockingly, the prescription pill industry uses questionable practices to increase their bottom line, and in turn, increase coding workload through unnecessary prescriptions. Though pharmaceutical companies have long-earned a reputation for wooing doctors with gifts, bribes, and incentives, it was only revealed in recent years that they’ve also been paying doctors huge sums of money to promote certain products. And, some and doctors are taking up on these offers.

These pre-selected medications are not only violating a conflict of interest, but they can also be largely responsible for increases in patient and insurance costs: a doctor may feel obligated to prescribe an expensive “sponsored” medication over a cheaper alternative.

Assessment

This in turn, is reflected on the overall rising cost of healthcare, which unfortunately, is exactly what the doctor ordered.

Conclusion

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Our Other Print Books and Related Information Sources:

Health Dictionary Series: http://www.springerpub.com/Search/marcinko

Practice Management: http://www.springerpub.com/product/9780826105752

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Hospitals: http://www.crcpress.com/product/isbn/9781439879900

Physician Advisors: www.CertifiedMedicalPlanner.org

Filed under: Drugs and Pharma, Ethics, Glossary Terms | Tagged: “sponsored” medication, Doctors on Drugs, pharma, pharmaceutical companies, prescription pills, Rx drugs | 7 Comments »

Doctors on Drugs?

Posted on December 7, 2011 by Dr. David Edward Marcinko MBA MEd CMP™

Sponsored Medications Increase MDs Bottom Line

Shockingly, the prescription pill industry has questionable practices to increase their bottom line, and in turn, increase coding workload through unnecessary prescriptions.

Though pharmaceutical companies have long-earned a reputation for wooing doctors with gifts, bribes, and incentives, it was only revealed in recent years that they’ve also been paying doctors huge sums of money to promote certain products – and doctors are taking up these offers. These pre-selected medications are not only violating a conflict of interest, they can be largely responsible for increases in patient and insurance costs: a doctor may feel obligated to prescribe an expensive “sponsored” medication over a cheaper alternative.

This in turn, is reflected on the overall rising cost of healthcare, which unfortunately, is exactly what the doctor ordered.

Source: Medical Billing and Coding

Conclusion

And so, your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Our Other Print Books and Related Information Sources:

Health Dictionary Series: http://www.springerpub.com/Search/marcinko

Practice Management: http://www.springerpub.com/product/9780826105752

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Sponsors Welcomed: And, credible sponsors and like-minded advertisers are always welcomed.

Link: https://healthcarefinancials.wordpress.com/2007/11/11/advertise

Filed under: Drugs and Pharma, Ethics | Tagged: Drugs, pharma, pharmaceutical companies, prescription pills, sponsored drugs | 1 Comment »

Enter Margaret Hamburg

Posted on April 10, 2009 by Dr. David Edward Marcinko MBA MEd CMP™

The New FDA Nominee

By Staff Reporters

According to Tracy Staton and FiercePharma on April 7, Dr. Marcia Angell, former New England Journal of Medicine editor-in-chief and current Harvard Medical School lecturer, wrote a column in the Washington Post that set out a list of seven goals for Margaret Hamburg who awaits senate confirmation as FDA chief.

A New Book

Now, Angell has a particular point of view; she’s published a book called The Truth About the Drug Companies [How they Deceive us and What to Do About It]. Here they are, presented for your critique and consideration by the new FDA chief:

Repeal the Prescription Drug User Fee Act because it puts “the FDA on the payroll of the industry it regulates.”
Consultants for drug companies should be banned from advisory committees.
Enforce FDA mandates on post-marketing studies.
Review generics as quickly as it checks out branded meds.
Require drug-makers to compare their new drugs with similar existing meds.
Cease surrogate drug endpoints.
Bar DTC ads for three years after a new drug is approved.

Assessment

What has she missed? Are these guidelines fair or not? Will they be advocated by Hamburg, if confirmed?

Conclusion

And so, your thoughts and comments on this Medical Executive-Post are appreciated? Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, be sure to subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com or Bio: www.stpub.com/pubs/authors/MARCINKO.htm

Get our Widget: Get this widget!

Our Other Print Books and Related Information Sources:

Practice Management: http://www.springerpub.com/prod.aspx?prod_id=23759

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Health Administration Terms: www.HealthDictionarySeries.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Filed under: Alerts Sign-Up, Book Reviews, Breaking News, Drugs and Pharma, Ethics, Health Law & Policy | Tagged: big-pharma, drug, drug companies, DTC, FDA, generic drugs, Marcia Angell, Margaret Hamburg, NEJM, pharma, pharmaceuticals, trade drugs, Washington Post | 1 Comment »

Subscribe MEDICAL EXECUTIVE-POST?

Member Statistics

ME-P Information & Content Channels

Ann Miller RN MHA [Managing Editor]

CERTIFIED MEDICAL PLANNER® program

Most Recent ME-Ps

PodiatryPrep.org

ME-P Free Advertising Consultation

Medical & Surgical e-Consent Forms

iMBA Inc., OFFICES

ME-P Publishing

SEEKING INDUSTRY INFO PARTNERS?

Reader Comments, Quips, Opinions, News & Updates

Start-Up Advice for Businesses, DRs and Entrepreneurs

Up-Trending ME-Ps

Capitalism and Free Enterprise Advocacy

OIG Fraud Warnings

CITE: https://tinyurl.com/2h47urt5

What’s up

What’s down

Share this:

Share this:

CITE: https://tinyurl.com/2h47urt5

🟢 What’s up

What’s down

Share this:

Share this:

Share this:

CITE: https://tinyurl.com/2h47urt5

🟢 What’s up

What’s down

Share this:

Defenses against a hostile takeover

Share this:

CITE: https://tinyurl.com/2h47urt5

Share this:

What’s up

What’s down

CITE: https://tinyurl.com/2h47urt5

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

In this article, with podcast, Bert collected the trends changing the pharmaceutical industry.

Share this:

Share this:

Share this:

[HEALTH INSURANCE, MANAGED CARE, ECONOMICS, FINANCE AND HEALTH INFORMATION TECHNOLOGY COMPANION DICTIONARY SET]

Share this:

Share this:

Share this:

Share this:

Share this:

Calendar

Advertising Info:

Book Offerings:

Dictionary Offerings:

Dr. David Marcinko [Publication List]

Education Online:

Health Dictionary Series Wiki Project

Lower Extremity Medicine & Surgery

Pending NIHCM Grant Applications:

Practice Lists:

Professor Marcinko

Related Blogs: